These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39224589)

  • 1. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
    Silva BA; Miglietta E; Casabona JC; Wenker S; Eizaguirre MB; Alonso R; Casas M; Lázaro LG; Man F; Portuondo G; Lopez Bisso A; Zavala N; Casales F; Imhoff G; Steinberg DJ; López PA; Carnero Contentti E; Deri N; Sinay V; Hryb J; Chiganer E; Leguizamon F; Tkachuk V; Bauer J; Ferrandina F; Giachello S; Henestroza P; Garcea O; Pascuale CA; Heitrich M; Podhajcer OL; Vinzón S; D'Alotto-Moreno T; Benatar A; Rabinovich GA; Pitossi FJ; Ferrari CC
    Front Immunol; 2024; 15():1431403. PubMed ID: 39224589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.
    Jameie M; Azizmohammad Looha M; Ebadi Z; Amanollahi M; Amani K; Nobahari F; Abdollahi A; Mousavi M; Pourghaz B; Harirchian MH
    BMC Neurol; 2024 Aug; 24(1):291. PubMed ID: 39164636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
    Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ
    Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    Habek M; Jakob Brecl G; Bašić Kes V; Rogić D; Barun B; Gabelić T; Emeršič A; Horvat Ledinek A; Grbić N; Lapić I; Šegulja D; Đurić K; Adamec I; Krbot Skorić M
    J Neuroimmunol; 2021 Oct; 359():577696. PubMed ID: 34418815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
    Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
    J Infect Dis; 2024 Jul; 230(1):e4-e16. PubMed ID: 39052718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
    Du PX; Chang SS; Ho TS; Shih HC; Tsai PS; Syu GD
    Virulence; 2024 Dec; 15(1):2351266. PubMed ID: 38717195
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Humoral and Cellular Immunity Following Asymptomatic SARS-CoV-2 Infection Compared to Symptomatic Infection in Education (The ACE Cohort).
    Hopkins G; Gomez N; Tucis D; Bartlett L; Steers G; Burns E; Brown M; Harvey-Cowlishaw T; Santos R; Lauder SN; Scurr M; Capitani L; Burnell S; Rees T; Smart K; Somerville M; Gallimore A; Perera M; Potts M; Metaxaki M; Krishna B; Jackson H; Tighe P; Onion D; Godkin A; Wills M; Fairclough L
    J Clin Immunol; 2024 Jun; 44(6):147. PubMed ID: 38856804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.